CO5150220A1 - 4-carboxiamino-2- metil-1,2,3,4-tetrahidroquinolinas - Google Patents
4-carboxiamino-2- metil-1,2,3,4-tetrahidroquinolinasInfo
- Publication number
- CO5150220A1 CO5150220A1 CO99057639A CO99057639A CO5150220A1 CO 5150220 A1 CO5150220 A1 CO 5150220A1 CO 99057639 A CO99057639 A CO 99057639A CO 99057639 A CO99057639 A CO 99057639A CO 5150220 A1 CO5150220 A1 CO 5150220A1
- Authority
- CO
- Colombia
- Prior art keywords
- substituted
- optionally
- mono
- carbon
- oxo
- Prior art date
Links
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 27
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 22
- 229910052757 nitrogen Chemical group 0.000 abstract 22
- 125000004043 oxo group Chemical group O=* 0.000 abstract 19
- 229910052799 carbon Inorganic materials 0.000 abstract 16
- 229920006395 saturated elastomer Polymers 0.000 abstract 16
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 15
- 229910052717 sulfur Inorganic materials 0.000 abstract 15
- 239000011593 sulfur Chemical group 0.000 abstract 15
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 11
- 229910052760 oxygen Inorganic materials 0.000 abstract 11
- 239000001301 oxygen Substances 0.000 abstract 11
- 125000005842 heteroatom Chemical group 0.000 abstract 10
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 10
- 229910052736 halogen Inorganic materials 0.000 abstract 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 8
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 6
- 125000004414 alkyl thio group Chemical group 0.000 abstract 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000001153 fluoro group Chemical group F* 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000002619 bicyclic group Chemical group 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 150000003973 alkyl amines Chemical class 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un compuesto de la fórmula I<EMI FILE="99057639_1" ID="1" IMF=JPEG >uno de sus profármacos, una sal farmacéuticamente aceptable de dicho compuesto o de dicho profármaco;en la que R1 es hidrógeno, Y, W-X, W-Y;en el que W es un carbonilo, tiocarbonilo, sulfinilo o sulfonilo;X es -a-Y, -S-Y, -N(H)-Y o -N-(Y)2;Y en cada caso es independientemente Z o una cadena de carbonos, lineal o ramificada, de uno a diez miembros, totalmente saturada, parcialmente insaturada o totalmente insaturada, en la que los carbonos, distintos del carbono de unión, pueden estar reemplazados opcionalmente por uno o dos heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno, y dicho carbono está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, dicho carbono está opcionalmente mono- sustituido con hidroxi, dicho carbono está opcionalmente mono-sustituido con oxo, dicho azufre está opcionalmente mono- o di-sustituido con oxo, dicho nitrógeno está opcionalmente mono- o di-sustituido con oxo y dicha cadena de carbonos está opcionalmente mono-sustituida con Z; en el que Z es un anillo, de tres a doce miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente uno a cuatro heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno, o un anillo bicíclico que consiste en dos anillos, de tres a seis miembros, fusionados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, teniendo opcionalmente de uno a cuatro heteroátomos seleccionados independientemente de nitrógeno, azufre y oxígeno;en el que dicho sustituyente Z está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, alquenilo(C2-C6), alquilo(C1-C6), hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxi, alquiloxi (C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6) en el que dicho sustituyente alquilo(C1-C6) está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxi, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6), estando dicho alquilo(C1-6) opcionalmente sustituido con uno a nueve átomos de flúor; R3 es hidrógeno o Q; en el que Q es una cadena de carbonos, lineal o ramificada, de uno a seis miembros, totalmente saturada, parcialmente insaturada o totalmente insaturada, en la que los carbonos, distintos del carbono de unión, pueden estar reemplazados opcionalmente por un heteroátomo- 2 - seleccionado de oxígeno, azufre y nitrógeno, y dicho carbono está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, dicho carbono está opcionalmente mono-sustituido con hidroxi, dicho carbono está opcionalmente mono-sustituido con oxo, dicho azufre está opcionalmente mono- o di-sustituido con oxo, dicho nitrógeno está opcionalmente mono- o di-sustituido con oxo y dicha cadena de carbonos está opcionalmente mono-sustituida con V; en el que V es un anillo, de tres a doce miembros parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene opcionalmente de uno a cuatro heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno, o un anillo bicíclico que consiste en dos anillos, de tres a seis miembros, fusionados, parcialmente saturados, totalmente saturados o totalmente insaturados, considerados independientemente, que tienen opcionalmente de uno a cuatro heteroátomos seleccionados independientemente de nitrógeno, azufre y oxígeno; en el que dicho sustituyente V está opcionalmente mono-, di-, tri o tetra-sustituido independientemente con halógeno, alquilo(C1-C6), alquenilo(C2-C6), hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxamoilo, mono-N- o di-N,N-alquil(C1-C6)-carboxamoilo, carboxi, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6), en el que dicho sustituyente alquilo(C1-C6) o alquenilo(C2-C6) está opcionalmente mono-, di- o tri-sustituido independientemente con hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxi, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N- alquilamillo(C1-C6), estando dicho alquilo(C1-C6) o alquenilo(C2-C6) opcionalmente sustituido con uno a nueve átomos de flúor; R4 esQ1 oV1; en el que Q1 es una cadena de carbonos, lineal o ramificada, de uno a seis miembros, totalmente saturada, parcialmente insaturada o totalmente insaturada, en la que los carbonos, distintos del carbono de unión, pueden estar reemplazados opcionalmente por un heteroátomo seleccionado de oxígeno, azufre y nitrógeno, y dicho carbono está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, dicho carbono está opcionalmente mono-sustituido con hidroxi, dicho carbono está opcionalmente mono-sustituido con oxo, dicho azufre está opcionalmente mono- o di-sustituido con oxo, dicho nitrógeno está opcionalmentc mono- o di-sustituido con oxo, y dicha cadena de carbonos está opcionalmente mono- sustituida con V1; en el que V1 es un anillo, de tres a seis miembros, parcialmente saturado, totalmente saturado o totalmente insaturado, que tiene uno a dos heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno; en el que dicho sustituyente V1 está opcionalmente mono-, di-, tri- o tetra-sustituido independientemente con halógeno, alquilo(C1-C6), alcoxi(C1-C6), amino, nitro, ciano, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6), en el que dicho sustituyente alquilo(C1-C6) está opcionalmente mono-sustituido con oxo, teniendo opcionalmente dicho sustituyente alquilo(C1-C6) de uno a nueve átomos de flúor; en la que R3 debe contener V o R4 debe contener V1; y R5, R6, R7, y R8 son cada uno independientemente hidrógeno, un enlace, nitro o halo, en el que dicho enlace está sustituido con T o una cadena de carbonos lineal o ramificada de (C1-C12) parcial o completamente saturada, o completamente insaturada, reemplazándose opcionalmente dicho carbono con uno o dos heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno, en el que dichos átomos de carbono están mono-, di- o tri-sustituidos independientemente con halo, dicho carbono está mono-sustituido con hidroxi, dicho carbono está mono-sustituido con oxo, dicho azufre está opcionalmente mono- o di-sustituido con oxo, dicho nitrógeno está opcionalmente mono- o di-sustituido con oxo, y dicho carbono está mono-sustituido con T; en el que T es un anillo de tres a doce miembros parcial o completamente saturado o completamente insaturado, que tiene opcionalmente uno a cuatro heteroátomos seleccionados independientemente de oxígeno, azufre y nitrógeno; o un anillo bicíclico que comprende dos anillos condensados de tres a seis miembros parcial o completamente saturado, o completamente insaturado, tomados independientemente, teniendo opcionalmente uno a cuatro heteroátomos seleccionados independientemente de nitrógeno, azufre y oxígeno; en la que dicho sustituyente T está opcionalmente mono-, di- o tri-sustituido independientemente con halógeno, alquilo(C1-C6), alquenilo(C2-C6), hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxi, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6) en el que dicho sustituyente alquilo(C1-C6) está opcionalmente mono-, di- o tri-sustituido independientemente con hidroxi, alcoxi(C1-C6), alquiltio(C1-C4), amino, nitro, ciano, oxo, carboxi, alquiloxi(C1-C6)-carbonilo, mono-N- o di-N,N-alquilamino(C1-C6), o teniendo dicho alquilo(C1-C6) opcionalmente uno a nueve átomos de flúor; con la condición de que R5, R6, R7 y R8 no sea hidrógeno y no esté enlazado al resto de quinolina a través de oxi.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10092998P | 1998-09-17 | 1998-09-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5150220A1 true CO5150220A1 (es) | 2002-04-29 |
Family
ID=22282259
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99057639A CO5150220A1 (es) | 1998-09-17 | 1999-09-10 | 4-carboxiamino-2- metil-1,2,3,4-tetrahidroquinolinas |
Country Status (25)
Country | Link |
---|---|
US (2) | US6147090A (es) |
EP (1) | EP1114033B1 (es) |
JP (1) | JP3655193B2 (es) |
AR (1) | AR021482A1 (es) |
AT (1) | ATE277906T1 (es) |
AU (1) | AU5439899A (es) |
BR (1) | BR9913842A (es) |
CA (1) | CA2344556A1 (es) |
CO (1) | CO5150220A1 (es) |
DE (1) | DE69920727T2 (es) |
DK (1) | DK1114033T3 (es) |
DZ (1) | DZ2889A1 (es) |
ES (1) | ES2228086T3 (es) |
GT (1) | GT199900149A (es) |
HN (1) | HN1999000155A (es) |
MA (1) | MA26687A1 (es) |
MY (1) | MY121838A (es) |
PA (1) | PA8481501A1 (es) |
PE (1) | PE20001048A1 (es) |
PT (1) | PT1114033E (es) |
SI (1) | SI1114033T1 (es) |
SV (1) | SV1999000149A (es) |
TN (1) | TNSN99172A1 (es) |
TW (1) | TWI232859B (es) |
WO (1) | WO2000017166A1 (es) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9602166D0 (en) * | 1996-02-02 | 1996-04-03 | Zeneca Ltd | Aminoheterocyclic derivatives |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
USRE44578E1 (en) | 2000-04-10 | 2013-11-05 | Teva Pharmaceutical Industries, Ltd. | Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids |
EP2382970B1 (en) | 2000-04-10 | 2013-01-09 | Teva Pharmaceutical Industries, Ltd. | Stable Pharmaceutical Compositions Containing 7-Substituted-3,5-Dihydroxyheptanoic Acids or 7-Substituted-3,5-Dihydroxyheptenoic Acids |
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
US6982251B2 (en) * | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
EP1911462A3 (en) | 2001-01-26 | 2011-11-30 | Schering Corporation | Compositions comprising a sterol absorption inhibitor |
US20060287254A1 (en) * | 2001-01-26 | 2006-12-21 | Schering Corporation | Use of substituted azetidinone compounds for the treatment of sitosterolemia |
AU2002306868A1 (en) * | 2001-03-28 | 2002-10-15 | Pharmacia Corporation | Therapeutic combinations for cardiovascular and inflammatory indications |
SE0101161D0 (sv) * | 2001-03-30 | 2001-03-30 | Astrazeneca Ab | New compounds |
BR0210505A (pt) * | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
BR0210519A (pt) | 2001-06-22 | 2004-06-22 | Pfizer Prod Inc | Composições farmacêuticas de adsorvatos de fármaco amorfo |
DE60233874D1 (de) * | 2001-06-22 | 2009-11-12 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
HUP0500165A2 (en) * | 2001-12-19 | 2006-09-28 | Atherogenics Inc | Chalcone derivatives and their use to treat diseases |
WO2003053359A2 (en) | 2001-12-19 | 2003-07-03 | Atherogenics, Inc. | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
BR0307344A (pt) * | 2002-02-01 | 2004-12-14 | Pfizer Prod Inc | Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica |
ES2309294T3 (es) * | 2002-02-01 | 2008-12-16 | Pfizer Products Inc. | Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo. |
US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
DE60311821T2 (de) | 2002-08-30 | 2007-10-31 | Japan Tobacco Inc. | Dibenzylaminverbindung und deren medizinische verwendung |
BR0315041A (pt) | 2002-10-04 | 2005-08-16 | Millennium Pharm Inc | Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica |
US20090181966A1 (en) * | 2002-10-04 | 2009-07-16 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
ATE327977T1 (de) * | 2002-10-21 | 2006-06-15 | Warner Lambert Co | Tetrahydrochinolin-derivate als crth2 antagonisten |
AU2003303239A1 (en) * | 2002-12-19 | 2004-07-14 | Atherogenics, Inc. | Process of making chalcone derivatives |
AU2003283769A1 (en) | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
US7208486B2 (en) | 2003-03-07 | 2007-04-24 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
MXPA05009848A (es) | 2003-03-17 | 2005-12-06 | Japan Tobacco Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo. |
AU2004222436A1 (en) * | 2003-03-17 | 2004-09-30 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate |
US20040204450A1 (en) * | 2003-03-28 | 2004-10-14 | Pfizer Inc | Quinoline and quinoxaline compounds |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
WO2004106299A2 (en) * | 2003-05-30 | 2004-12-09 | Ranbaxy Laboratories Limited | Substituted pyrrole derivatives and their use as hmg-co inhibitors |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
WO2005011635A2 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
US7317025B2 (en) | 2003-09-24 | 2008-01-08 | Johnson & Johnson Pharmaceutical Research & Development, Llc | Non-peptidic NPY Y2 receptor inhibitors |
WO2005030185A2 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
KR20060085675A (ko) * | 2003-10-08 | 2006-07-27 | 일라이 릴리 앤드 캄파니 | 이상지혈증 치료를 위한 화합물 및 방법 |
EP1918000A2 (en) | 2003-11-05 | 2008-05-07 | Schering Corporation | Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
PT1732933E (pt) | 2004-03-26 | 2008-10-20 | Lilly Co Eli | Compostos para o tratamento da dislipidémia |
TWI345568B (en) | 2004-04-02 | 2011-07-21 | Mitsubishi Tanabe Pharma Corp | Tetrahydronaphthyridine derivatives and a process for preparing the same |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
US20060063828A1 (en) * | 2004-06-28 | 2006-03-23 | Weingarten M D | 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
JP2008514718A (ja) * | 2004-09-29 | 2008-05-08 | シェーリング コーポレイション | 置換アゼチドノンおよびcb1アンタゴニストの組み合わせ |
ES2435790T3 (es) | 2004-12-03 | 2013-12-23 | Intervet International B.V. | Piperazinas sustituidas como antagonistas de CB1 |
US7700774B2 (en) * | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
EP2548894A1 (en) | 2005-02-03 | 2013-01-23 | Bend Research, Inc. | Pharmaceutical compositions with enhanced performance |
ZA200707498B (en) | 2005-02-24 | 2008-11-26 | Millennium Pharm Inc | PGD2 receptor antagonists for the treatment of inflammatory diseases |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
KR101329112B1 (ko) | 2005-11-08 | 2013-11-14 | 랜박시 래보러터리스 리미티드 | (3r,5r)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법 |
CA2637565A1 (en) | 2006-01-18 | 2007-07-26 | Schering Corporation | Cannibinoid receptor modulators |
UY30118A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compueto amina trisustituido |
UY30117A1 (es) | 2006-01-31 | 2007-06-29 | Tanabe Seiyaku Co | Compuesto amina trisustituido |
CA2637768C (en) | 2006-02-07 | 2014-07-29 | F. Hoffmann-La Roche Ag | Benzamide and heteroarene derivatives |
WO2008020314A2 (en) * | 2006-03-14 | 2008-02-21 | Ranbaxy Laboratories Limited | Statin stabilizing dosage formulations |
WO2007107843A1 (en) * | 2006-03-22 | 2007-09-27 | Pfizer Products Inc. | Methods of treatment with cetp inhibitors |
TW200808731A (en) | 2006-03-30 | 2008-02-16 | Tanabe Seiyaku Co | A process for preparing tetrahydroquinoline derivatives |
MX2009000439A (es) * | 2006-07-14 | 2009-02-04 | Ranbaxy Lab Ltd | Formas polimorficas de un inhibidor de hmg-coa reductasa y usos de las mismas. |
US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
JP5244095B2 (ja) | 2007-04-13 | 2013-07-24 | 興和株式会社 | 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬 |
WO2008130616A2 (en) * | 2007-04-19 | 2008-10-30 | Schering Corporation | Diaryl morpholines as cb1 modulators |
KR20100051625A (ko) | 2007-06-28 | 2010-05-17 | 인터벳 인터내셔널 비.브이. | Cb1 길항제로서의 치환된 피페라진 |
EP2170847A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
CA2703203C (en) | 2007-10-22 | 2015-12-15 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
AU2009249237A1 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as GPR119 modulators |
WO2010009195A1 (en) | 2008-07-16 | 2010-01-21 | Schering Corporation | Bicyclic heterocycle derivatives and use thereof as gpr119 modulators |
EP2379547A1 (en) | 2008-12-16 | 2011-10-26 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
WO2010075271A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
JP2012513469A (ja) | 2008-12-23 | 2012-06-14 | シェーリング コーポレイション | ピリミジン誘導体及びその使用法 |
EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
AR076024A1 (es) | 2009-04-03 | 2011-05-11 | Schering Corp | Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos |
AU2010313469A1 (en) | 2009-10-29 | 2012-06-07 | Merck Sharp & Dohme Corp. | Bridged Bicyclic Piperidine Derivatives and methods of use thereof |
WO2011062889A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Pyrimidine ether derivatives and methods of use thereof |
WO2011062885A1 (en) | 2009-11-23 | 2011-05-26 | Schering Corporation | Fused bicyclic pyrimidine derivatives and methods of use thereof |
WO2011066137A1 (en) | 2009-11-24 | 2011-06-03 | Schering Corporation | Substituted biaryl derivatives and methods of use thereof |
WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
MX2017002610A (es) | 2014-08-29 | 2017-10-11 | Tes Pharma S R L | INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA. |
EP3866802A1 (en) * | 2018-10-17 | 2021-08-25 | Duke University | Quinone reductase 2 inhibitors for use as neuroprotective agents |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
US5276168A (en) * | 1990-06-18 | 1994-01-04 | E. R. Squibb & Sons, Inc. | Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents |
US5401848A (en) * | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
JPH0676403B2 (ja) * | 1991-01-18 | 1994-09-28 | エスエス製薬株式会社 | 新規なベンゾ[5,6 シクロヘプタ[1,2−b ピリジン誘導体及びこれを含有する抗アレルギー剤 |
US5288725A (en) * | 1992-10-15 | 1994-02-22 | Merck & Co., Inc. | Pyrroloquinoline Bradykinin antagonist |
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
DE19627431A1 (de) | 1996-07-08 | 1998-01-15 | Bayer Ag | Heterocyclisch kondensierte Pyridine |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
US6462091B1 (en) | 1998-12-23 | 2002-10-08 | G.D. Searle & Co. | Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications |
-
1999
- 1999-09-07 US US09/391,273 patent/US6147090A/en not_active Expired - Fee Related
- 1999-09-08 PA PA19998481501A patent/PA8481501A1/es unknown
- 1999-09-09 HN HN1999000155A patent/HN1999000155A/es unknown
- 1999-09-10 WO PCT/IB1999/001529 patent/WO2000017166A1/en active IP Right Grant
- 1999-09-10 DE DE69920727T patent/DE69920727T2/de not_active Expired - Fee Related
- 1999-09-10 AU AU54398/99A patent/AU5439899A/en not_active Abandoned
- 1999-09-10 PE PE1999000923A patent/PE20001048A1/es not_active Application Discontinuation
- 1999-09-10 EP EP99940421A patent/EP1114033B1/en not_active Expired - Lifetime
- 1999-09-10 CA CA002344556A patent/CA2344556A1/en not_active Abandoned
- 1999-09-10 MY MYPI99003922A patent/MY121838A/en unknown
- 1999-09-10 ES ES99940421T patent/ES2228086T3/es not_active Expired - Lifetime
- 1999-09-10 GT GT199900149A patent/GT199900149A/es unknown
- 1999-09-10 DK DK99940421T patent/DK1114033T3/da active
- 1999-09-10 JP JP2000574076A patent/JP3655193B2/ja not_active Expired - Fee Related
- 1999-09-10 PT PT99940421T patent/PT1114033E/pt unknown
- 1999-09-10 CO CO99057639A patent/CO5150220A1/es unknown
- 1999-09-10 AR ARP990104556A patent/AR021482A1/es active IP Right Grant
- 1999-09-10 AT AT99940421T patent/ATE277906T1/de not_active IP Right Cessation
- 1999-09-10 BR BR9913842-5A patent/BR9913842A/pt not_active Application Discontinuation
- 1999-09-10 TW TW088115690A patent/TWI232859B/zh not_active IP Right Cessation
- 1999-09-10 SV SV1999000149A patent/SV1999000149A/es not_active Application Discontinuation
- 1999-09-10 SI SI9930672T patent/SI1114033T1/xx unknown
- 1999-09-13 MA MA25764A patent/MA26687A1/fr unknown
- 1999-09-13 TN TNTNSN99172A patent/TNSN99172A1/fr unknown
- 1999-09-17 DZ DZ990189A patent/DZ2889A1/xx active
-
2000
- 2000-09-27 US US09/671,400 patent/US6395751B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
TWI232859B (en) | 2005-05-21 |
DE69920727T2 (de) | 2006-03-09 |
GT199900149A (es) | 2001-03-03 |
PA8481501A1 (es) | 2001-12-14 |
AU5439899A (en) | 2000-04-10 |
WO2000017166A1 (en) | 2000-03-30 |
EP1114033B1 (en) | 2004-09-29 |
DK1114033T3 (da) | 2004-12-20 |
BR9913842A (pt) | 2001-06-12 |
SI1114033T1 (en) | 2005-02-28 |
CA2344556A1 (en) | 2000-03-30 |
DE69920727D1 (en) | 2004-11-04 |
TNSN99172A1 (fr) | 2005-11-10 |
ES2228086T3 (es) | 2005-04-01 |
AR021482A1 (es) | 2002-07-24 |
US6395751B1 (en) | 2002-05-28 |
DZ2889A1 (fr) | 2003-12-15 |
EP1114033A1 (en) | 2001-07-11 |
ATE277906T1 (de) | 2004-10-15 |
MA26687A1 (fr) | 2004-12-20 |
PE20001048A1 (es) | 2000-10-17 |
US6147090A (en) | 2000-11-14 |
PT1114033E (pt) | 2004-12-31 |
JP2002526477A (ja) | 2002-08-20 |
HN1999000155A (es) | 2000-01-12 |
JP3655193B2 (ja) | 2005-06-02 |
SV1999000149A (es) | 2000-07-06 |
MY121838A (en) | 2006-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5150220A1 (es) | 4-carboxiamino-2- metil-1,2,3,4-tetrahidroquinolinas | |
CO5290250A1 (es) | 1, 2, 3, 4-tetrahidroquinolinas 2-sustituidas 4-amino sustituidas | |
CO5370678A1 (es) | 1,2,3,4-tetrahidroquinolinas 2-sustituidas 4-carboxiamino sustituidas | |
CO5080735A1 (es) | Agonistas de prostaglandinas | |
AR090649A2 (es) | Inhibidores del virus de la hepatitis c | |
ES2259113T3 (es) | Inhibidores del factor xa y de otras serinproteasas implicadas en la cascada de coagulacion. | |
ES2505091T3 (es) | Compuestos, composiciones y métodos de uso de ftalazina | |
CO5320600A1 (es) | Agentes antibacterianos de 3-aminoquinazolin-2,4-dionas | |
CO5170502A1 (es) | Derivados de 1-carboxi-n-cyclopropyl-4-(quinolin o naftil -4-iloxi) pirrolidin-2-carboxamide y sus composiciones farmaceuticas | |
CO5261578A1 (es) | Inhibidores de nitrilo de dipeptido catepsina k. | |
MY152153A (en) | Macrocylic inhibitors of hepatitis c virus | |
PE20011189A1 (es) | Inhibidores de las metaloproteasas que contienen cadenas laterales heterociclicas | |
CO5130004A1 (es) | 1-aril-3-arilmetil-1,8-naftiridin-4(1h)-onas | |
ES2531149T3 (es) | Derivados de 2-piridiniletilcarboxamida y su uso como fungicidas | |
CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
CO5150150A1 (es) | 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales | |
ECSP066632A (es) | El uso de derivados de n-arilhidrazina para combatir pestes en y sobre animales | |
AR063529A1 (es) | Compuestos de pirazolina | |
AR072508A1 (es) | Inhibidores alfa 7 nicotinicos del receptor de acetilcolina | |
CL2008003431A1 (es) | Compuestos derivados de nucleosidos 2',4' sustituidos; proceso de preparacion de dichos compuestos; composicion farmaceutica que los comprende; su metodo de preparacion; y su uso para el tratamiento y/o la prevencion de cualquier condicion resultante de una infeccion por vhb, vhc o vih. | |
AR054630A1 (es) | Compuestos de n- tio-antranilamida y su uso como pesticidas | |
CO5190697A1 (es) | Aminoalcoxicarbazoles para el tratamiento de enfermedades del snc | |
CO6180506A2 (es) | Inhibidores de la proteasa ns3 del hcv | |
PE20051056A1 (es) | Compuestos de 1-(azolin-2-il)amino-1,2-difeniletano para combatir insectos, aracnidos y nematodos | |
SE0300956D0 (sv) | Stabilisatorblandningar |